title: Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?
authors.affiliation: *Preclinical Development †Clinical Development, R&D Alfa Wassermann SpA, Bologna, Italy.
authors.forename: Fiorella
authors.initials: F
authors.lastname: Calanni
authors.forename: Cecilia
authors.initials: C
authors.lastname: Renzulli
authors.forename: Maria V
authors.initials: MV
authors.lastname: Fogli
authors.forename: Miriam
authors.initials: M
authors.lastname: Barbanti
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D012294:Rifamycins / Q000494:pharmacology*
chemical_list: D000890:Anti-Infective Agents; D012294:Rifamycins